Valproic acid hepatic fatalities. II. US experience since 1984.
about
Molecular and therapeutic potential and toxicity of valproic acidGuidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin.Metabolic disease in the fetus predisposes to maternal hepatic complications of pregnancyTreatment of valproic acid-associated hepatic failure with orthotopic liver transplantationValproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicityFatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate hepatotoxicity in adultsInappropriate liver transplantation in a child with Alpers-Huttenlocher syndrome misdiagnosed as valproate-induced acute liver failureValproic acid and fatalities in children: a review of individual case safety reports in VigiBaseCarbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation.Quantitative determination of valproic acid and 14 metabolites in serum and urine by gas chromatography/mass spectrometry.Topiramate enhances the risk of valproate-associated side effects in three children.Age-related differences in susceptibility to cisplatin-induced renal toxicity.The role of carnitine supplementation during valproic acid therapy.Rational approach to treatment options for Lennox-Gastaut syndrome.Idiosyncratic reactions: new methods of identifying high-risk patients.Apoptosis in diseases of the liver.Safety and tolerability of antiepileptic drug treatment in children with epilepsy.Idiosyncratic drug reactions: a mechanistic evaluation of risk factorsPancreatitis associated with valproic acid: a review of the literature.Identifying genomic and developmental causes of adverse drug reactions in children.Children versus adults: pharmacokinetic and adverse-effect differences.Valproate.Use of antiepileptic drugs in childhood epilepsyDifferentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptiInfluence of co-medication on the metabolism of valproate.Therapeutic drug monitoring of old and newer anti-epileptic drugs.Apparent autoinduction of valproate beta-oxidation in humansFebrile seizures: four steps algorithmic clinical approach.Drug-resistant epilepsia and fulminant valproate liver toxicity. Alpers-Huttenlocher syndrome in two children confirmed post mortem by identification of p.W748S mutation in POLG geneCase files of the Children's Hospital of Michigan Regional Poison Control Center: the use of carnitine for the management of acute valproic acid toxicity.Idiosyncratic adverse reactions to antiepileptic drugs.Drug metabolite profiling and elucidation of drug-induced hepatotoxicity.Choosing the correct antiepileptic drugs: from animal studies to the clinic.Hepatotoxicity associated with antiepileptic drugs.Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.First seizure - to treat or not to treat?Effects of valproic acid on organic acid metabolism in children: a metabolic profiling studyFebrile convulsions. How dangerous are they?Developmental pharmacogenomics.Specific safety and tolerability considerations in the use of anticonvulsant medications in children.
P2860
Q21296867-083BA04E-D77F-4112-B04E-768138AEF372Q24514895-A4030B7A-4BD6-4165-9AE8-0FCEA9E44F5EQ28142066-2A0CBFF9-0ED6-4218-80E5-0E5141C969D5Q28320266-9E82184C-1100-4D66-B441-5272CFE56BA3Q28324498-D9187258-FEA8-4ADB-9FD4-9AB7317D8B8AQ28369097-CBEE7954-76DF-4B8E-AA3B-1C52B4B190E0Q28374079-D82EA168-B770-4614-B6C6-166BA668CBCCQ28543695-AF36F6E3-2831-430D-97F8-DD18C5D93EC1Q30728586-FAA8840D-79F3-4FA9-B2E4-C0E0BC262299Q33218447-621999F5-5888-4507-B05A-3CBF6BAD9542Q33341929-8B6654F6-ED38-4319-9E96-FE57BB3C82A3Q33691277-A4BFD322-29A2-4305-BA72-D89A4BB8C789Q33941948-F8A6AEDC-00C2-4453-93D9-024FC39E0329Q33971818-DAF38363-7E48-4D34-95C4-9FB4E7CA5B65Q34090578-78EF95AA-2677-4DAD-8339-6DC88468828DQ34248399-9B8FDE5C-A57F-4AB9-9AF6-C4A1F81DE630Q34281872-247A1F28-8E6D-4E08-B07C-50E3FA472E6CQ34403403-57D1320F-8F9B-4B23-B4BB-766C7A8F9029Q34476918-79AEABCA-6AB2-480A-8418-1668E282EBABQ34603032-DDD074ED-B9EB-46B7-A589-02F2C9431C91Q34680689-1C229E6E-55D2-47DE-BD33-1ADAFCC18725Q35142736-07B10451-33B4-4242-B15E-529EA43466FEQ35627524-544B2FE1-EF4C-4DC8-8051-90E7E1DB9682Q35690870-31B90C14-EC88-4DB5-AB2C-91E37F715F5BQ35690874-0B111470-9A62-462A-8A05-58063195272EQ35970354-571B2BE3-1719-494F-9F70-D9CD19E4C39CQ36055180-1AA2E20F-A547-4CD5-80E3-55FA4740AF58Q36244365-8C6E361C-2304-498F-B1BC-D6AC7DF1C451Q36516391-4B787F73-820C-4485-806F-E73DFF128BA2Q36548488-5CC8ECCA-5062-46AA-AFCD-3D7C52E601D0Q36770454-25C2F4E6-140A-47EF-A2FA-B7FC3E566BEEQ36835826-EE7E59D5-FCA5-4598-8F4F-5F9216679A30Q37086272-22B8A823-FA32-4013-A700-C17ED1EB5AF5Q37110313-FA3716EB-5872-44BC-9FBE-25D65A657F0CQ37130104-05F2547D-0AA0-4916-B033-94D026D638F7Q37270800-979184CD-BFEC-417F-A60E-C6DCBA88A49BQ37294747-D123C34C-4F4A-439B-A5F7-19BF011EE5DAQ37677502-E4E96BA5-EF74-457A-B3C4-8D33F1FA526AQ37841723-75A69A6B-50D0-4313-93D2-1100ACEC6B43Q38026034-70B2B2F9-B983-4574-BDD8-8796139565CA
P2860
Valproic acid hepatic fatalities. II. US experience since 1984.
description
1989 nî lūn-bûn
@nan
1989 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Valproic acid hepatic fatalities. II. US experience since 1984.
@ast
Valproic acid hepatic fatalities. II. US experience since 1984.
@en
type
label
Valproic acid hepatic fatalities. II. US experience since 1984.
@ast
Valproic acid hepatic fatalities. II. US experience since 1984.
@en
prefLabel
Valproic acid hepatic fatalities. II. US experience since 1984.
@ast
Valproic acid hepatic fatalities. II. US experience since 1984.
@en
P2093
P356
P1433
P1476
Valproic acid hepatic fatalities. II. US experience since 1984.
@en
P2093
D H Langer
F E Dreifuss
J E Maxwell
K A Moline
P304
P356
10.1212/WNL.39.2.201
P407
P433
P577
1989-02-01T00:00:00Z